Trial Profile
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Jan 2024
Price :
$35
*
At a glance
- Drugs Ad26.COV2 S (Primary)
- Indications COVID-19 respiratory infection
- Focus Registrational; Therapeutic Use
- Acronyms ENSEMBLE 2
- Sponsors Janssen Pharmaceuticals; Janssen Vaccines and Prevention B.V; Johnson & Johnson Innovative Medicine
- 21 Jul 2023 Status changed from active, no longer recruiting to completed.
- 06 Jul 2022 Planned End Date changed from 20 Jun 2023 to 30 Jun 2023.
- 06 Jul 2022 Planned primary completion date changed from 10 May 2022 to 19 Jun 2023.